Evidence map›Paper›PMID 34755809›Full record

ArticleEinstein (Sao Paulo, Brazil)2021

High mortality among patients with cancer and COVID-19 infection: the experience of a Brazilian cancer center.

Lilian Arruda do Rêgo Barros, Marcos Aurélio Fonseca Magalhães Filho, Rafaela de Brito Alves, Camilla Vieira de Rebouças, Cicilia Marques Rodrigues, Micaela Mazutti Viu, Vinicius de Lima Benedito, Alayne Magalhães Trindade Domingues Yamada, Auro Del Giglio, Felipe José Silva Melo Cruz

Open access · diamondAbstract read
In one paragraph

Article in Einstein (Sao Paulo, Brazil), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Lilian Arruda do Rêgo BarrosInstituto Brasileiro de Controle do Câncer, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0002-7101-4325
Marcos Aurélio Fonseca Magalhães FilhoCentro Universitário FMABC, Santo André, SP, Brazil.ORCID http://orcid.org/0000-0002-2467-315X
Rafaela de Brito AlvesInstituto Brasileiro de Controle do Câncer, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0002-5416-1163
Camilla Vieira de RebouçasInstituto Brasileiro de Controle do Câncer, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0001-7333-398X
Cicilia Marques RodriguesInstituto Brasileiro de Controle do Câncer, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0003-0464-2492
Micaela Mazutti ViuInstituto Brasileiro de Controle do Câncer, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0002-2325-3313
Vinicius de Lima BeneditoCentro Universitário São Camilo, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0002-4535-9821
Alayne Magalhães Trindade Domingues YamadaInstituto Brasileiro de Controle do Câncer, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0001-9778-6123
Auro Del GiglioCentro Universitário FMABC, Santo André, SP, Brazil.ORCID http://orcid.org/0000-0002-2009-824X
Felipe José Silva Melo CruzInstituto Brasileiro de Controle do Câncer, São Paulo, SP, Brazil.ORCID http://orcid.org/0000-0002-4558-4850
Instituto Brasileiro de Controle do Câncer · BRFaculdade de Medicina do ABC · BRCentro Universitário São Camilo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the severity of COVID-19 in cancer patients to describe clinical and epidemiological factors associated with poor outcomes (mortality and need of intensive care unit admission or mechanical ventilation).

methodsRetrospective data from patients with cancer and laboratory diagnosis of COVID-19, obtained between March 16 and May 29, 2020, were retrieved out of a cancer center database. Data analyzed included patient history, age, sex, comorbidities, types of cancer and anticancer therapy.

resultsThis sample comprised 105 patients aged 18-92 years, 80.9% of whom were females. Dyspnea was the most prevalent initial symptom (30.4%) among patients who died (p<0.0001). Overall, 57.1% of patients had metastatic disease and 60% had poor performance status (Eastern Cooperative Oncologic Group ≥2) at the time of COVID-19 diagnosis. The overall mortality rate was 40.95%. Mortality rates were higher in male patients and those with poor performance status (p<0.0001).

conclusionThis cohort is one of the largest Brazilian studies describing clinical and epidemiological features of patients with cancer and concurrent COVID-19. Findings of this study emphasize the vulnerability of cancer patients in the current pandemic, and indicate high mortality from COVID-19 among male cancer patients and cancer patients with poor performance status. This analysis may assist the selection of patients who may benefit from strict isolation and eventual discontinuation of anticancer therapy to reduce exposure to infection.

Indexed as

COVID-19NeoplasmsComorbidityCOVID-19 TestingFemaleHospitalizationHumansMaleRespiration, ArtificialRetrospective StudiesRisk FactorsSARS-CoV-2

Identifiers

PMID34755809
PMCPMC8555874
OpenAlexW3209100796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.